AtaiBeckley Inc (ATAI)

• Market cap: $1.35B
• 1 day: -14.06%
• 5 days: -2.61%
• 1 month: -4.36%
• 3 months: -0.53%
• 6 months: -22.77%
• Year to date: -3.62%
• 1 year: 115.61%
• 5 years: -80.82%
• 10 years: -80.82%
• Sector: Healthcare
• Industry: Biotechnology

About: AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Employees: 54